Journal
BLOOD
Volume 130, Issue 16, Pages 1785-1794Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2017-03-773374
Keywords
-
Categories
Funding
- Swedish Research Council
- Swedish Cancer Society
- Cancer and Allergy Foundation
- Stockholm Cancer Society (Radiumhemmets Forskningsfonder)
- Tore Nilson's Foundation for Medical Research
- Ollie and Elof Ericsson Foundation
- Hans von Kantzow's Foundation
- Karolinska Institutet
Ask authors/readers for more resources
Human hematopoietic progenitors are generally assumed to require stem cell factor (SCF) and KIT signaling during differentiation for the formation of mast cells. Imatinib treatment, which inhibits KIT signaling, depletes mast cells in vivo. Furthermore, the absence of SCF or imatinib treatment prevents progenitors from developing into mast cells in vitro. However, these observations do not mean that mast cell progenitors require SCF and KIT signaling throughout differentiation. Here, we demonstrate that circulating mast cell progenitors are present in patients undergoing imatinib treatment. In addition, we show that mast cell progenitors from peripheral blood survive, mature, and proliferate without SCF and KIT signaling in vitro. Contrary to the prevailing consensus, our results show that SCF and KIT signaling are dispensable for early mast cell development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available